A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Neuralstem
  • Most Recent Events

    • 08 Aug 2017 According to a Neuralstem media release, the company will continue to data from this trial and provide a full update in the fourth quarter of 2017.
    • 25 Jul 2017 Results published in a Neuralstem Media Release.
    • 25 Jul 2017 Primary endpoint has not been met. (Montgomery-Asberg Depression Rating Scale (MADRS)), according to a Neuralstem media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top